(NASDAQ: IDYA) Ideaya Biosciences's forecast annual revenue growth rate of -30% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 98.72%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.78%.
Ideaya Biosciences's revenue in 2025 is $214,834,000.On average, 21 Wall Street analysts forecast IDYA's revenue for 2026 to be $4,576,712,496, with the lowest IDYA revenue forecast at $0, and the highest IDYA revenue forecast at $15,459,971,051. On average, 18 Wall Street analysts forecast IDYA's revenue for 2027 to be $9,786,201,125, with the lowest IDYA revenue forecast at $4,850,933,020, and the highest IDYA revenue forecast at $17,340,415,502.
In 2028, IDYA is forecast to generate $20,459,586,299 in revenue, with the lowest revenue forecast at $10,616,402,009 and the highest revenue forecast at $42,774,193,791.